Monopar Therapeutics Inc Cash Flow Conversion Efficiency
Monopar Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Monopar Therapeutics Inc (MNPR) has a cash flow conversion efficiency ratio of -24.817x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.25 Billion) by net assets ($130.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Monopar Therapeutics Inc (2015–2025)
Cash flow conversion efficiency of Monopar Therapeutics Inc from 2015 to 2025. This chart illustrates how Monopar Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MNPR stock price for real-time trading data and today's change.
Monopar Therapeutics Inc Cash Flow Conversion Ratio Explained
Monopar Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Monopar Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Monopar Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Monopar Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Chenming Paper Holdings Ltd
SHE:000488
|
-0.036x |
|
MBM Resources Bhd
KLSE:5983
|
0.008x |
|
Kedge Construction Co Ltd
TW:2546
|
-0.134x |
|
Akis Gayrimenkul Yatirim Ortakligi AS
IS:AKSGY
|
0.014x |
|
Shakti Pumps (India) Limited
NSE:SHAKTIPUMP
|
-0.280x |
|
Juniper Hotels Ltd
NSE:JUNIPER
|
0.061x |
|
Gourmet Master Co Ltd
TW:2723
|
0.053x |
|
Ackerstein Group Ltd
TA:ACKR
|
0.042x |
Annual Cash Flow Conversion Efficiency for Monopar Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Monopar Therapeutics Inc from 2015 to 2025. Review financial flexibility index of Monopar Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $137.83 Million | $-12.20 Million | -0.089x | +23.92% |
| 2024-12-31 | $55.04 Million | $-6.40 Million | -0.116x | +91.73% |
| 2023-12-31 | $5.59 Million | $-7.86 Million | -1.406x | -96.30% |
| 2022-12-31 | $10.09 Million | $-7.23 Million | -0.716x | -85.45% |
| 2021-12-31 | $18.94 Million | $-7.32 Million | -0.386x | -30.03% |
| 2020-12-31 | $15.69 Million | $-4.66 Million | -0.297x | -24.33% |
| 2019-12-31 | $12.63 Million | $-3.02 Million | -0.239x | +42.73% |
| 2018-12-31 | $6.92 Million | $-2.89 Million | -0.417x | -52.76% |
| 2017-12-31 | $9.62 Million | $-2.63 Million | -0.273x | +35.27% |
| 2016-12-31 | $2.83 Million | $-1.19 Million | -0.422x | -82.64% |
| 2015-12-31 | $2.75 Million | $-636.33K | -0.231x | -- |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more